ACHV vs. VNRX, TKNO, ABIO, AWH, ICCC, RGLS, CRVO, ELMD, MCRB, and CO
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include VolitionRx (VNRX), Alpha Teknova (TKNO), ARCA biopharma (ABIO), Aspira Women's Health (AWH), ImmuCell (ICCC), Regulus Therapeutics (RGLS), CervoMed (CRVO), Electromed (ELMD), Seres Therapeutics (MCRB), and Global Cord Blood (CO). These companies are all part of the "medical" sector.
Achieve Life Sciences (NASDAQ:ACHV) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
Achieve Life Sciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
Achieve Life Sciences has higher earnings, but lower revenue than VolitionRx. Achieve Life Sciences is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
In the previous week, Achieve Life Sciences and Achieve Life Sciences both had 2 articles in the media. Achieve Life Sciences' average media sentiment score of 0.72 beat VolitionRx's score of 0.30 indicating that Achieve Life Sciences is being referred to more favorably in the media.
Achieve Life Sciences currently has a consensus price target of $17.25, indicating a potential upside of 266.24%. VolitionRx has a consensus price target of $2.50, indicating a potential upside of 233.33%. Given Achieve Life Sciences' higher probable upside, equities research analysts plainly believe Achieve Life Sciences is more favorable than VolitionRx.
Achieve Life Sciences received 326 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 70.15% of users gave Achieve Life Sciences an outperform vote while only 27.27% of users gave VolitionRx an outperform vote.
33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 2.0% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 15.4% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Achieve Life Sciences has a net margin of 0.00% compared to VolitionRx's net margin of -4,557.29%. VolitionRx's return on equity of 0.00% beat Achieve Life Sciences' return on equity.
Summary
Achieve Life Sciences beats VolitionRx on 9 of the 14 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
